Abstract:Abstract Radiation therapy in combination with chemotherapy is the primary treatment for lung cancer patients with surgically unresectable tumors or locally advanced diseases. Unfortunately, about one third of these patients develop clinically significant toxicities. This not only severely limits the dosage of radiation that can be delivered, but also negatively impacts patients’ quality of life. Commonly used clinical variables are insufficient to predict the occurrence of these toxicities prior to treatment. This has led to interest in examining the influence of genetic variability in patient toxicity following radiotherapy. Several small scale association studies with only limited samples and markers have provided evidence of genetic contribution to the risk of developing radiation-induced toxicity, while most lack validation. To identify reliable genetic variants associated with risk of developing clinically significant radiation-induced toxicities, we conducted a genome wide scan of 300,977 single-nucleotide polymorphisms (SNPs) in 393 non-small cell lung cancer (NSCLC) Caucasian patients who received definitive radiation therapy at the University of Texas MD Anderson Cancer Center (discovery phase). We assessed the association of each SNP with the two major forms of radiation-induced toxicities (pneumonitis and esophagitis) via a multivariate logistic regression model. A total of 30,474 SNPs were significantly associated with pneumonitis (651 SNPs reached P<10−3, 45 SNPs reached P<10−4) and 31,086 with esophagitis (687 SNPs reached P<10−3, 59 SNPs reached P<10−4). The most significant SNPs for pneumonitis and esophagitis were located in chromosome 10q (OR=3.24, 95%CI=2.06-5.08, P=3.18×10−7) and chromosome 4p (OR=0.17, 95%CI=0.08-0.37, P=9.42×10−6), respectively. The results from discovery phase showed no evidence for inflation of the test statistics (inflation factor of dominant model =1.065 for both outcomes). We then performed classification and regression tree (CART) analysis to explore high-order gene-gene interactions among top SNPs (P<10−3) in modulating toxicities. Four SNPs for pneumonitis and four SNPs for esophagitis were identified by CART to have significant interactions in modulating the risk of developing toxicities. A validation phase for the most significant SNPs in an additional 275 NSCLC patients treated in a similar fashion is currently ongoing. To our knowledge, this is the first genome-wide association study to identify SNPs associated with toxicities resulting from definitive radiation therapy in NSCLC patients. With this relatively large sample size, we expect to identify novel susceptibility loci that may play a significant role in contributing to the development of radiation-induced toxicities. This will assist in the development of more personalized radiotherapy delivery and symptom management. Citation Format: Xia Pu, Heath D. Skinner, Yuanqing Ye, Michelle AT Hildebrandt, Joe Y. Chang, Charles Lu, Ritsuko Komaki, John D. Minna, Jack A. Roth, Xifeng Wu. Genome-wide association study of toxicity following definitive radiotherapy in non-small cell lung cancer patients. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4582. doi:10.1158/1538-7445.AM2013-4582

MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer.

Prognostic Biomarkers after Radiotherapy for Nonsmall Cell Lung Cancer Based on Bioinformatics Analysis

Abstract 3626: Inflammation-related Genetic Variants Predict Radiation-Induced Toxicity Following Definitive Radiotherapy for Non-Small Cell Lung Cancer.

Genetic Variants In Inflammation-Related Genes Are Associated With Radiation-Induced Toxicity Following Treatment For Non-Small Cell Lung Cancer

Inflammation-related Genetic Variants Predict Toxicity Following Definitive Radiotherapy for Lung Cancer.

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Age-related Common Mirna Polymorphism Associated with Severe Toxicity in Lung Cancer Patients Treated with Platinum-Based Chemotherapy.

Association Between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer

Abstract 4582: Genome-wide Association Study of Toxicity Following Definitive Radiotherapy in Non-Small Cell Lung Cancer Patients.

A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

Associations of Genetic Variations in MicroRNA Seed Regions With Acute Adverse Events and Survival in Patients With Rectal Cancer Receiving Postoperative Chemoradiation Therapy.

Abstract 77: Genetic Variations in the Stem Cell Pathway Predict for Toxicity Following Radiotherapy in Lung Cancer.

Abstract A3: MicroRNA-related Polymorphisms Are Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients

MicroRNA-Related Genetic Variants As Predictors of Early Stage Non–Small Cell Lung Cancer Clinical Outcomes

Predicting Severe Radiation Pneumonitis in Patients with Locally- Advanced Non-Small Cell Lung Cancer after Thoracic Radiotherapy: Development and Internal Validation of a Nomogram Based on the Clinical, Hematological and Dose–volume Histogram Parameters

Analysis of Genetic Variants and the Cerna Network of Mir-9 in Non-Small Cell Lung Cancer

Abstract PR-03: Genetic Variations in Microrna Biogenesis Genes As Predictors for Risk of Second Primary Tumor (SPT) And/or Recurrence in Patients with Early-Stage Head and Neck Cancer

Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response.

Genetic Variants in MTHFR Gene Predict ≥ 2 Radiation Pneumonitis in Esophageal Squamous Cell Carcinoma Patients Treated with Thoracic Radiotherapy.

Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer

MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.